State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches

Bruno A. Cesca , Kali Pellicer San Martin , Matías D. Caverzan , Paula M. Oliveda , Luis E. Ibarra

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002303

PDF (9189KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002303 DOI: 10.37349/etat.2025.1002303
Review
research-article
State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches
Author information +
History +
PDF (9189KB)

Abstract

Glioblastoma (GBM), the most aggressive and lethal primary brain tumor, poses a significant therapeutic challenge due to its highly invasive nature and resistance to conventional therapies, including surgery, chemotherapy, and radiotherapy. Despite advances in standard treatments, patient survival remains limited, requiring the exploration of innovative strategies. Photodynamic therapy (PDT) has emerged as a promising approach, leveraging light-sensitive photosensitizers (PSs), molecular oxygen, and specific light wavelengths to generate reactive oxygen species (ROS) that selectively induce tumor cell death. Originally developed for skin cancer, PDT has evolved to target more complex malignancies, including GBM. The refinement of second- and third-generation PS, coupled with advancements in nanotechnology, has significantly improved PDT’s selectivity, bioavailability, and therapeutic efficacy. Moreover, the combination of PDT with chemotherapy, targeted therapy, and immunotherapy, among other therapeutic modalities, has shown potential in enhancing therapeutic outcomes. This review provides a comprehensive analysis of the preclinical and clinical applications of PDT in GBM, detailing its mechanisms of action, the evolution of PS, and novel combinatory strategies that optimize treatment efficacy. However, several challenges remain, including overcoming GBM-associated hypoxia, enhancing PS delivery across the blood-brain barrier, and mitigating tumor resistance mechanisms. The integration of PDT with molecular and genetic insight, alongside cutting-edge nanotechnology-based delivery systems, may revolutionize GBM treatment, offering new prospects for improved patient survival and quality of life.

Keywords

Glioblastoma / nanoparticles / photosensitizers / resistance mechanisms / combination therapy

Cite this article

Download citation ▾
Bruno A. Cesca, Kali Pellicer San Martin, Matías D. Caverzan, Paula M. Oliveda, Luis E. Ibarra. State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002303 DOI:10.37349/etat.2025.1002303

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Manrique-Guzmán S, Herrada-Pineda T, Revilla-Pacheco F. Surgical Management of Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017. pp. 243-61.

[2]

Caverzan MD, Ibarra LE. Advancing glioblastoma treatment through iron metabolism: A focus on TfR1 and Ferroptosis innovations. Int J Biol Macromol. 2024; 278: 134777.

[3]

Miller JJ. Targeting IDH-Mutant Glioma. Neurotherapeutics. 2022; 19: 1724-32.

[4]

Shi H, Sadler PJ. How promising is phototherapy for cancer? Br J Cancer. 2020; 123: 871-3.

[5]

Akimoto J, Fukami S, Ichikawa M, Mohamed A, Kohno M. Intraoperative Photodiagnosis for Malignant Glioma Using Photosensitizer Talaporfin Sodium. Front Surg. 2019; 6: 12.

[6]

Maruyama T, Muragaki Y, Nitta M, Tsuzuki S, Yasuda T, Ikuta S, et al. Photodynamic Therapy for Malignant Brain Tumors. Jpn J Neurosurg. 2016; 25: 895-904. Japanese.

[7]

Ibarra LE. Development of nanosystems for active tumor targeting in photodynamic therapy. Ther Deliv. 2022; 13: 71-4.

[8]

Li G, Wang C, Jin B, Sun T, Sun K, Wang S, et al. Advances in smart nanotechnology-supported photodynamic therapy for cancer. Cell Death Discov. 2024; 10: 466.

[9]

Moradi S, Akhavan O, Tayyebi A, Rahighi R, Mohammadzadeh M, Saligheh Rad HR. Magnetite/dextran-functionalized graphene oxide nanosheets for in vivo positive contrast magnetic resonance imaging. RSC Adv. 2015; 5: 47529-37.

[10]

Amani H, Habibey R, Hajmiresmail SJ, Latifi S, Pazoki-Toroudi H, Akhavan O. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. J Mater Chem B. 2017; 5: 9452-76.

[11]

Ranji-Burachaloo H, Gurr PA, Dunstan DE, Qiao GG. Cancer Treatment through Nanoparticle-Facilitated Fenton Reaction. ACS Nano. 2018; 12: 11819-37.

[12]

Ibarra LE, Camorani S, Agnello L, Pedone E, Pirone L, Chesta CA, et al. Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles. Pharmaceutics. 2022; 14: 626.

[13]

Cheng B, Ahn HH, Nam H, Jiang Z, Gao FJ, Minn I, et al. A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects. Pharmaceutics. 2022; 14: 373.

[14]

Assali A, Akhavan O, Adeli M, Razzazan S, Dinarvand R, Zanganeh S, et al. Multifunctional core-shell nanoplatforms (gold@graphene oxide) with mediated NIR thermal therapy to promote miRNA delivery. Nanomedicine. 2018; 14: 1891-903.

[15]

Liu SF, Li MJ, Liang B, Sun W, Shao Y, Hu X, et al. Breaking the barrier: Nanoparticle-enhanced radiotherapy as the new vanguard in brain tumor treatment. Front Pharmacol. 2024; 15: 1394816.

[16]

Yabo YA, Heiland DH. Understanding glioblastoma at the single-cell level: Recent advances and future challenges. PLoS Biol. 2024; 22:e3002640.

[17]

Khasraw M, Fujita Y, Lee-Chang C, Balyasnikova IV, Najem H, Heimberger AB. New Approaches to Glioblastoma. Annu Rev Med. 2022; 73: 279-92.

[18]

Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016; 134: 381-97.

[19]

Nam JY, de Groot JF. Treatment of Glioblastoma. J Oncol Pract. 2017; 13: 629-38.

[20]

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014; 16: 896-913.

[21]

Gunasegaran B, Ashley CL, Marsh-Wakefield F, Guillemin GJ, Heng B. Viruses in glioblastoma: an update on evidence and clinical trials. BJC Rep. 2024; 2: 33.

[22]

Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme - an overview. Contemp Oncol (Pozn). 2014; 18: 307-12. Polish.

[23]

Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015; 129: 829-48.

[24]

Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19: 764-72.

[25]

Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70: 299-312.

[26]

Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022; 32:e13062.

[27]

Yu D, Liu Y, Zhou Y, Ruiz-Rodado V, Larion M, Xu G, et al. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proc Natl Acad Sci U S A. 2020; 117: 9964-72.

[28]

Krigers A, Pinggera D, Demetz M, Kornberger LM, Kerschbaumer J, Thomé C, et al. The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV. Front Neurol. 2022; 13: 900377.

[29]

Mikic N, Gentilal N, Cao F, Lok E, Wong ET, Ballo M, et al. Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose-response relationships. Neurooncol Adv. 2024; 6: vdae032.

[30]

Bähr O, Tabatabai G, Fietkau R, Goldbrunner R, Glas M. Tumor treating fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study. JCO. 2024; 42: 2036.

[31]

Zhang L, Ren Y, Peng Y, Luo Y, Liu Y, Wang X, et al. Tumor treating fields for newly diagnosed high-grade glioma based on the criteria of 2021 WHO CNS5: A retrospective analysis of Chinese patients in a single center. Cancer Med. 2024; 13: e7350.

[32]

Ibarra LE, Vilchez ML, Caverzán MD, Milla Sanabria LN. Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events. J Neurosci Res. 2021; 99: 1024-47.

[33]

Nagai K, Akimoto J, Fukami S, Saito Y, Ogawa E, Takanashi M, et al. Efficacy of interstitial photodynamic therapy using talaporfin sodium and a semiconductor laser for a mouse allograft glioma model. Sci Rep. 2024; 14: 9137.

[34]

Stummer W, Müther M, Spille D. Beyond fluorescence-guided resection: 5-ALA-based glioblastoma therapies. Acta Neurochir (Wien). 2024; 166: 163.

[35]

Lilge L, Portnoy M, Wilson BC. Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer. 2000; 83: 1110-7.

[36]

Caverzán MD, Oliveda PM, Beaugé L, Palacios RE, Chesta CA, Ibarra LE. Metronomic Photodynamic Therapy with Conjugated Polymer Nanoparticles in Glioblastoma Tumor Microenvironment. Cells. 2023; 12: 1541.

[37]

Saito Y, Fukami S, Nagai K, Ogawa E, Kuroda M, Kohno M, et al. Cytocidal Effects of Interstitial Photodynamic Therapy Using Talaporfin Sodium and a Semiconductor Laser in a Rat Intracerebral Glioma Model. Biomedicines. 2024; 12: 2141.

[38]

Marinho MAG, da Silva Marques M, de Oliveira Vian C, de Moraes Vaz Batista Filgueira D, Horn AP. Photodynamic therapy with curcumin and near-infrared radiation as an antitumor strategy to glioblastoma cells. Toxicol In Vitro. 2024; 100: 105917.

[39]

Pevna V, Wagnières G, Huntosova V. Autophagy and Apoptosis Induced in U87 MG Glioblastoma Cells by Hypericin-Mediated Photodynamic Therapy Can Be Photobiomodulated with 808 nm Light. Biomedicines. 2021; 9: 1703.

[40]

Mishchenko T, Balalaeva I, Gorokhova A, Vedunova M, Krysko DV. Which cell death modality wins the contest for photodynamic therapy of cancer? Cell Death Dis. 2022; 13: 455.

[41]

Turubanova VD, Balalaeva IV, Mishchenko TA, Catanzaro E, Alzeibak R, Peskova NN, et al. Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine. J Immunother Cancer. 2019; 7: 350.

[42]

Zhang Y, Doan BT, Gasser G. Metal-Based Photosensitizers as Inducers of Regulated Cell Death Mechanisms. Chem Rev. 2023; 123: 10135-55.

[43]

Bai W, Xue Y, Guo Y, Zhang D, Ma K, Chen Z, et al. Reactive oxygen species produced by photodynamic therapy enhance docosahexaenoic acid lipid peroxidation and induce the death of breast cancer cells. Colloids Surf B Biointerfaces. 2024; 241: 114012.

[44]

Xiong T, Chen Y, Peng Q, Lu S, Long S, Li M, et al. Lipid Droplet Targeting Type I Photosensitizer for Ferroptosis via Lipid Peroxidation Accumulation. Adv Mater. 2024; 36: e2309711.

[45]

Zhou W, Lim A, Elmadbouh OHM, Edderkaoui M, Osipov A, Mathison AJ, et al. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells. Free Radic Biol Med. 2024; 212: 493-504.

[46]

Cui S, Guo X, Wang S, Wei Z, Huang D, Zhang X, et al. Singlet Oxygen in Photodynamic Therapy. Pharmaceuticals (Basel). 2024; 17: 1274.

[47]

Xu L, Hu J, Yan X, Zhao H, Geng M, Zhang J, et al. Overcoming therapeutic limitations in glioblastoma treatment: A nanocomposite inducing ferroptosis and oxeiptosis via Photodynamic therapy. Chem Eng J. 2024; 500: 157405.

[48]

Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022; 39: 102915.

[49]

Fakudze N, Abrahamse H, George B. Nanoparticles improved pheophorbide-a mediated photodynamic therapy for cancer. Lasers Med Sci. 2025; 40: 78.

[50]

Sun C, Wang Y, Tang Q, Yang D, Hou L, Cao Z, et al. Tumor microenvironment activated and amplified self-luminescent nano photosensitizers for efficient treatment of triple negative breast cancer. Chem Eng J. 2024; 494: 152400.

[51]

Benayoun L, Schaffer M, Bril R, Gingis-Velitski S, Segal E, Nevelsky A, et al. Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy. Cancer Biol Ther. 2013; 14: 64-74.

[52]

Shi Y, Zhang F, Linhardt RJ. Porphyrin-based compounds and their applications in materials and medicine. Dye Pigment. 2021; 188: 109136.

[53]

Hsia T, Small JL, Yekula A, Batool SM, Escobedo AK, Ekanayake E, et al. Systematic Review of Photodynamic Therapy in Gliomas. Cancers (Basel). 2023; 15: 3918.

[54]

Cramer SW, Chen CC. Photodynamic Therapy for the Treatment of Glioblastoma. Front Surg. 2020; 6: 81.

[55]

Leroy HA, Baert G, Guerin L, Delhem N, Mordon S, Reyns N, et al. Interstitial Photodynamic Therapy for Glioblastomas: A Standardized Procedure for Clinical Use. Cancers (Basel). 2021; 13: 5754.

[56]

Dupont C, Vermandel M, Leroy HA, Quidet M, Lecomte F, Delhem N, et al. INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial. Neurosurgery. 2019; 84: E414-9.

[57]

Fujishiro T, Nonoguchi N, Pavliukov M, Ohmura N, Kawabata S, Park Y, et al. 5-Aminolevulinic acid-mediated photodynamic therapy can target human glioma stem-like cells refractory to antineoplastic agents. Photodiagnosis Photodyn Ther. 2018; 24: 58-68.

[58]

Neagu M, Constantin C, Tampa M, Matei C, Lupu A, Manole E, et al. Toxicological and efficacy assessment of post-transition metal (Indium) phthalocyanine for photodynamic therapy in neuroblastoma. Oncotarget. 2016; 7: 69718-32.

[59]

Marcus SL, Sobel RS, Golub AL, Carroll RL, Lundahl S, Shulman DG. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg. 1996; 14: 59-66.

[60]

Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 2010; 7: 61-75.

[61]

Casas A. Clinical uses of 5-aminolaevulinic acid in photodynamic treatment and photodetection of cancer: A review. Cancer Lett. 2020; 490: 165-73.

[62]

Beck TJ, Burkanas M, Bagdonas S, Krivickiene Z, Beyer W, Sroka R, et al. Two-photon photodynamic therapy of C6 cells by means of 5-aminolevulinic acid induced protoporphyrin IX. J Photochem Photobiol B. 2007; 87: 174-82.

[63]

Lopez RF, Lange N, Guy R, Bentley MV. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev. 2004; 56: 77-94.

[64]

Naidoo C, Kruger CA, Abrahamse H. Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma. Molecules. 2019; 24: 3153.

[65]

Novotny A, Stummer W. 5-Aminolevulinic Acid and the Blood-Brain Barrier - A Review. Med Laser Appl. 2003; 18: 36-40.

[66]

Pacioni S, D’Alessandris QG, Giannetti S, Della Pepa GM, Offi M, Giordano M, et al. 5-Aminolevulinic Acid (5-ALA)-Induced Protoporphyrin IX Fluorescence by Glioma Cells-A Fluorescence Microscopy Clinical Study. Cancers (Basel). 2022; 14: 2844.

[67]

Bhanja D, Wilding H, Baroz A, Trifoi M, Shenoy G, Slagle-Webb B, et al. Photodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability. Cancers (Basel). 2023; 15: 3427.

[68]

Jones PS, Yekula A, Lansbury E, Small JL, Ayinon C, Mordecai S, et al. Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma. EBioMedicine. 2019; 48: 23-35.

[69]

Meng Z, Xue H, Wang T, Chen B, Dong X, Yang L, et al. Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical. J Nanobiotechnology. 2022; 20: 344.

[70]

Sokol MB, Beganovskaya VA, Mollaeva MR, Yabbarov NG, Chirkina MV, Belykh DV, et al. Pharmaceutical Approach to Develop Novel Photosensitizer Nanoformulation: An Example of Design and Characterization Rationale of Chlorophyll α Derivative. Pharmaceutics. 2024; 16: 126.

[71]

Kubota F, Satrialdi, Takano Y, Maeki M, Tokeshi M, Harashima H, et al. Fine-tuning the encapsulation of a photosensitizer in nanoparticles reveals the relationship between internal structure and phototherapeutic effects. J Biophotonics. 2023; 16: e202200119.

[72]

Zhang Y, Zhao M, Cheng D, Zhu J, Cheng B, Miao M, et al. Self-Assembled Type I Nanophotosensitizer with NIR-II Fluorescence Emission for Imaging-Guided Targeted Phototherapy of Glioblastoma. ACS Appl Nano Mater. 2024; 7: 22117-29.

[73]

Dixit S, Novak T, Miller K, Zhu Y, Kenney ME, Broome AM. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015; 7: 1782-90.

[74]

Cesca BA, Caverzan MD, Lamberti MJ, Ibarra LE. Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy. Int J Mol Sci. 2024; 25: 7525.

[75]

Yamaguchi S, Kobayashi H, Narita T, Kanehira K, Sonezaki S, Kubota Y, et al. Novel photodynamic therapy using water-dispersed TiO2-polyethylene glycol compound: evaluation of antitumor effect on glioma cells and spheroids in vitro. Photochem Photobiol. 2010; 86: 964-71.

[76]

Jardón-Guadarrama G, Manríquez-Ramírez ME, Rodríguez-Pérez CE, Díaz-Ruiz A, de los Ángeles Martínez-Cárdenas M, Mata-Bermudez A, et al. TiO2-ZnPc nanoparticles functionalized with folic acid as a target photosensitizer for photodynamic therapy against glioblastoma cells. J Mater Sci Mater Med. 2024; 35: 1-13.

[77]

Meyers JD, Cheng Y, Broome AM, Agnes RS, Schluchter MD, Margevicius S, et al. Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer. Part Part Syst Charact. 2015; 32: 448-57.

[78]

Seabra MABL, Dubois LG, dos Santos-Júnior EF, Cavalcanti Santos RV, de Castro Neto AG, Isaac AR, et al. CdTe quantum dots as fluorescent nanotools for in vivo glioblastoma imaging. Opt Mater X. 2024; 21: 100282.

[79]

Zhang C, Zhao X, Li D, Ji F, Dong A, Chen X, et al. Advances in 5-aminoketovaleric acid(5-ALA) nanoparticle delivery system based on cancer photodynamic therapy. J Drug Deliv Sci Technol. 2022; 78: 103933.

[80]

Wang X, Tian Y, Liao X, Tang Y, Ni Q, Sun J, et al. Enhancing selective photosensitizer accumulation and oxygen supply for high-efficacy photodynamic therapy toward glioma by 5-aminolevulinic acid loaded nanoplatform. J Colloid Interface Sci. 2020; 565: 483-93.

[81]

Zhang M, Jiang X, Zhang Q, Zheng T, Mohammadniaei M, Wang W, et al. Biodegradable Polymeric Nanoparticles Containing an Immune Checkpoint Inhibitor (aPDL1) to Locally Induce Immune Responses in the Central Nervous System. Adv Funct Mater. 2021; 31: 2102274.

[82]

Foresto E, Gilardi P, Ibarra LE, Cogno IS. Light-activated green drugs: How we can use them in photodynamic therapy and mass-produce them with biotechnological tools. Phytomedicine Plus. 2021; 1: 100044.

[83]

Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010; 24: 317-24.

[84]

Luiza Andreazza N, Vevert-Bizet C, Bourg-Heckly G, Sureau F, José Salvador M, Bonneau S. Berberine as a photosensitizing agent for antitumoral photodynamic therapy: Insights into its association to low density lipoproteins. Int J Pharm. 2016; 510: 240-9.

[85]

Grimland JL, Wu C, Ramoutar RR, Brumaghim JL, McNeill J. Photosensitizer-doped conjugated polymer nanoparticles with high cross-sections for one- and two-photon excitation. Nanoscale. 2011; 3: 1451-5.

[86]

Meng Z, Hou W, Zhou H, Zhou L, Chen H, Wu C. Therapeutic Considerations and Conjugated Polymer-Based Photosensitizers for Photodynamic Therapy. Macromol Rapid Commun. 2018; 39: 1700614.

[87]

Ponzio RA, Ibarra LE, Achilli EE, Odella E, Chesta CA, Martínez SR, et al. Sweet light o’ mine: Photothermal and photodynamic inactivation of tenacious pathogens using conjugated polymers. J Photochem Photobiol B. 2022; 234: 112510.

[88]

Wang X, Wu M, Li H, Jiang J, Zhou S, Chen W, et al. Enhancing Penetration Ability of Semiconducting Polymer Nanoparticles for Sonodynamic Therapy of Large Solid Tumor. Adv Sci (Weinh). 2022; 9: e2104125.

[89]

Spada RM, Macor LP, Hernández LI, Ponzio RA, Ibarra LE, Lorente C, et al. Amplified singlet oxygen generation in metallated-porphyrin doped conjugated polymer nanoparticles. Dye Pigment. 2018; 149: 212-23.

[90]

Feyen PLC, Matarèse BFE, Urbano L, Abelha TF, Rahmoune H, Green M, et al. Photosensitized and Photothermal Stimulation of Cellular Membranes by Organic Thin Films and Nanoparticles. Front Bioeng Biotechnol. 2022; 10: 932877.

[91]

Ortiz Ortiz AM, George O, Jasim K, Gesquiere AJ. Photodynamic Therapy with Conjugated Polymer Nanoparticles: Recent Advances and Therapeutic Considerations. J Cancer Treat Diagnosis. 2018; 2: 1-6.

[92]

Ibarra LE, Porcal GV, Macor LP, Ponzio RA, Spada RM, Lorente C, et al. Metallated porphyrin-doped conjugated polymer nanoparticles for efficient photodynamic therapy of brain and colorectal tumor cells. Nanomedicine (Lond). 2018; 13: 605-24.

[93]

Caverzán MD, Beaugé L, Chesta CA, Palacios RE, Ibarra LE. Photodynamic therapy of Glioblastoma cells using doped conjugated polymer nanoparticles: An in vitro comparative study based on redox status. J Photochem Photobiol B. 2020; 212: 112045.

[94]

Dilenko H, Bartoň Tománková K, Válková L, Hošíková B, Kolaříková M, Malina L, et al. Graphene-Based Photodynamic Therapy and Overcoming Cancer Resistance Mechanisms: A Comprehensive Review. Int J Nanomedicine. 2024; 19: 5637-80.

[95]

Akhavan O, Ghaderi E, Emamy H. Nontoxic concentrations of PEGylated graphene nanoribbons for selective cancer cell imaging and photothermal therapy. J Mater Chem. 2012; 22: 20626-33.

[96]

Yan X, Niu G, Lin J, Jin AJ, Hu H, Tang Y, et al. Enhanced fluorescence imaging guided photodynamic therapy of sinoporphyrin sodium loaded graphene oxide. Biomaterials. 2015; 42: 94-102.

[97]

Kalluru P, Vankayala R, Chiang CS, Hwang KC. Nano-graphene oxide-mediated In vivo fluorescence imaging and bimodal photodynamic and photothermal destruction of tumors. Biomaterials. 2016; 95: 1-10.

[98]

Wang B, Guo H, Xu H, Chen Y, Zhao G, Yu H. The Role of Graphene Oxide Nanocarriers in Treating Gliomas. Front Oncol. 2022; 12: 736177.

[99]

Zhu H, Feng R, Li D, Shi M, Wang N, Wang Y, et al. A multifunctional graphene oxide-based nanodrug delivery system for tumor targeted diagnosis and treatment under chemotherapy-photothermal-photodynamic synergy. Colloids Surf B Biointerfaces. 2025; 248: 114479.

[100]

Wang Y, Wang H, Liu D, Song S, Wang X, Zhang H. Graphene oxide covalently grafted upconversion nanoparticles for combined NIR mediated imaging and photothermal/photodynamic cancer therapy. Biomaterials. 2013; 34: 7715-24.

[101]

Akhavan O, Ghaderi E. Flash photo stimulation of human neural stem cells on graphene/TiO2 heterojunction for differentiation into neurons. Nanoscale. 2013; 5: 10316-26.

[102]

Ławkowska K, Pokrywczyńska M, Koper K, Kluth LA, Drewa T, Adamowicz J. Application of Graphene in Tissue Engineering of the Nervous System. Int J Mol Sci. 2021; 23: 33.

[103]

Saadati M, Akhavan O, Fazli H, Nemati S, Baharvand H. Controlled Differentiation of Human Neural Progenitor Cells on Molybdenum Disulfide/Graphene Oxide Heterojunction Scaffolds by Photostimulation. ACS Appl Mater Interfaces. 2023; 15: 3713-30.

[104]

Park SY, Park J, Sim SH, Sung MG, Kim KS, Hong BH, et al. Enhanced differentiation of human neural stem cells into neurons on graphene. Adv Mater. 2011; 23: H263-7.

[105]

Hong SW, Lee JH, Kang SH, Hwang EY, Hwang YS, Lee MH, et al. Enhanced neural cell adhesion and neurite outgrowth on graphene-based biomimetic substrates. Biomed Res Int. 2014; 2014: 212149.

[106]

Fabbri R, Scidà A, Saracino E, Conte G, Kovtun A, Candini A, et al. Graphene oxide electrodes enable electrical stimulation of distinct calcium signalling in brain astrocytes. Nat Nanotechnol. 2024; 19: 1344-53.

[107]

Arias-Ramos N, Ibarra LE, Serrano-Torres M, Yagüe B, Caverzán MD, Chesta CA, et al. Iron Oxide Incorporated Conjugated Polymer Nanoparticles for Simultaneous Use in Magnetic Resonance and Fluorescent Imaging of Brain Tumors. Pharmaceutics. 2021; 13: 1258.

[108]

Chen Y, Ma Y, Shi K, Chen H, Han X, Wei C, et al. Self-Disassembling and Oxygen-Generating Porphyrin-Lipoprotein Nanoparticle for Targeted Glioblastoma Resection and Enhanced Photodynamic Therapy. Adv Mater. 2024; 36: e2307454.

[109]

Guo B, Sheng Z, Hu D, Liu C, Zheng H, Liu B. Through Scalp and Skull NIR-II Photothermal Therapy of Deep Orthotopic Brain Tumors with Precise Photoacoustic Imaging Guidance. Adv Mater. 2018; 30: e1802591.

[110]

Nuthalapati K, Vankayala R, Shanmugam M, Thangudu S, Chiang CS, Hwang KC. Engineering Tumor-Specific Nanotheranostic Agent with MR Image-Guided NIR-II & -III Photodynamic Therapy to Combat Against Deeply Seated Orthotopic Glioblastoma. Small Sci. 2024; 4: 2400191.

[111]

Cheng W, Duan Z, Chen H, Wang Y, Wang C, Pan Y, et al. Macrophage membrane-camouflaged pure-drug nanomedicine for synergistic chemo- and interstitial photodynamic therapy against glioblastoma. Acta Biomater. 2025; 193: 392-405.

[112]

Yin Y, Tang W, Ma X, Tang L, Zhang Y, Yang M, et al. Wang, Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma. Chem Eng J. 2022; 433: 133848.

[113]

Liu P, Lan S, Gao D, Hu D, Chen Z, Li Z, et al. Targeted blood-brain barrier penetration and precise imaging of infiltrative glioblastoma margins using hybrid cell membrane-coated ICG liposomes. J Nanobiotechnology. 2024; 22: 603.

[114]

Lv B, Zhao Y, Liang Y, Cao J. Extracellular vesicles: An advanced delivery platform for photosensitizers in tumor photodynamic therapy. Chem Eng J. 2024; 498: 155438.

[115]

Poinsot V, Pizzinat N, Ong-Meang V. Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery. Nanomaterials (Basel). 2024; 14: 639.

[116]

Fang X, Gong R, Yang D, Li C, Zhang Y, Wang Y, et al. NIR-II Light-Driven Genetically Engineered Exosome Nanocatalysts for Efficient Phototherapy against Glioblastoma. J Am Chem Soc. 2024; 146: 15251-63.

[117]

Hill ML, Chung SJ, Woo HJ, Park CR, Hadrick K, Nafiujjaman M, et al. Exosome-Coated Prussian Blue Nanoparticles for Specific Targeting and Treatment of Glioblastoma. ACS Appl Mater Interfaces. 2024; 16: 20286-301.

[118]

Osman H, Elsahy D, Saadatzadeh MR, Pollok KE, Yocom S, Hattab EM, et al. Acridine Orange as a Novel Photosensitizer for Photodynamic Therapy in Glioblastoma. World Neurosurg. 2018; 114: e1310-5.

[119]

Alkahtani S, S Al-Johani N, Alarifi S, Afzal M. Cytotoxicity Mechanisms of Blue-Light-Activated Curcumin in T98G Cell Line: Inducing Apoptosis through ROS-Dependent Downregulation of MMP Pathways. Int J Mol Sci. 2023; 24: 3842.

[120]

Makarov VI, Skobeltsin AS, Averchuk AS, Berdnikov AK, Chinenkova MV, Salmina AB, et al. Effect of Photodynamic Therapy with the Photosensitizer Methylene Blue on Cerebral Endotheliocytes In Vitro. Photonics. 2024; 11: 316.

[121]

Schipmann S, Müther M, Stögbauer L, Zimmer S, Brokinkel B, Holling M, et al. Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. J Neurosurg. 2020; 134: 426-36.

[122]

Stepp H, Stummer W. 5-ALA in the management of malignant glioma. Lasers Surg Med. 2018; 50: 399-419.

[123]

Stepp H, Beck T, Pongratz T, Meinel T, Kreth FW, Tonn JCh, et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol. 2007; 26: 157-64.

[124]

Walke A, Krone C, Stummer W, König S, Suero Molina E. Protoporphyrin IX in serum of high-grade glioma patients: A novel target for disease monitoring via liquid biopsy. Sci Rep. 2024; 14: 4297.

[125]

Pepper NB, Eich HT, Müther M, Oertel M, Rehn S, Spille DC, et al. ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma. Radiat Oncol. 2024; 19: 11.

[126]

Kaneko S, Fujimoto S, Yamaguchi H, Yamauchi T, Yoshimoto T, Tokuda K. Photodynamic Therapy of Malignant Gliomas. Prog Neurol Surg. 2018; 32: 1-13.

[127]

Kaneko S, Kaneko S. Fluorescence-Guided Resection of Malignant Glioma with 5-ALA. Int J Biomed Imaging. 2016; 2016: 6135293.

[128]

Muragaki Y, Akimoto J, Maruyama T, Iseki H, Ikuta S, Nitta M, et al. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J Neurosurg. 2013; 119: 845-52.

[129]

Kostron H, Obwegeser A, Jakober R. Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B. 1996; 36: 157-68.

[130]

Zimmermann A, Ritsch-Marte M, Kostron H. mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol. 2001; 74: 611-6.

[131]

Eljamel MS, Goodman C, Moseley H. ALA and Photofrin® Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci. 2008; 23: 361-7.

[132]

Lyons M, Phang I, Eljamel S. The effects of PDT in primary malignant brain tumours could be improved by intraoperative radiotherapy. Photodiagnosis Photodyn Ther. 2012; 9: 40-5.

[133]

Eljamel S, Petersen M, Valentine R, Buist R, Goodman C, Moseley H, et al. Comparison of intraoperative fluorescence and MRI image guided neuronavigation in malignant brain tumours, a prospective controlled study. Photodiagnosis Photodyn Ther. 2013; 10: 356-61.

[134]

Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol. 1995; 11: 346-54.

[135]

Bogaards A, Varma A, Zhang K, Zach D, Bisland SK, Moriyama EH, et al. Fluorescence image-guided brain tumour resection with adjuvant metronomic photodynamic therapy: pre-clinical model and technology development. Photochem Photobiol Sci. 2005; 4: 438-42.

[136]

Akimoto J, Fukami S, Suda T, Ichikawa M, Haraoka R, Kohno M, et al. First autopsy analysis of the efficacy of intra-operative additional photodynamic therapy for patients with glioblastoma. Brain Tumor Pathol. 2019; 36: 144-51.

[137]

Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858-64.

[138]

Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med. 2006; 38: 489-93.

[139]

Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell. 2006; 10: 241-52.

[140]

Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors. Strahlenther Onkol. 2012; 188: 616-27.

[141]

Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004; 64: 2120-6.

[142]

Seta KA, Spicer Z, Yuan Y, Lu G, Millhorn DE. Responding to hypoxia: lessons from a model cell line. Sci STKE. 2002; 2002: re11.

[143]

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016; 352: 175-80.

[144]

Kanamori M, Higa T, Sonoda Y, Murakami S, Dodo M, Kitamura H, et al. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients. Neuro Oncol. 2015; 17: 555-65.

[145]

Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004; 10: 549-57.

[146]

Ahmad F, Dixit D, Sharma V, Kumar A, Joshi SD, Sarkar C, et al. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma. Cell Death Dis. 2016; 7: e2213.

[147]

Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013; 123: 2921-34.

[148]

Rocha CR, Kajitani GS, Quinet A, Fortunato RS, Menck CF. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget. 2016; 7: 48081-92.

[149]

Dokic I, Hartmann C, Herold-Mende C, Régnier-Vigouroux A. Glutathione peroxidase 1 activity dictates the sensitivity of glioblastoma cells to oxidative stress. Glia. 2012; 60: 1785-800.

[150]

Zhu Z, Du S, Du Y, Ren J, Ying G, Yan Z. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. J Neurochem. 2018; 144: 93-104.

[151]

Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci. 2005; 12: 389-98.

[152]

Zhang Y, Ding C, Zhu W, Li X, Chen T, Liu Q, et al. Chemotherapeutic drugs induce oxidative stress associated with DNA repair and metabolism modulation. Life Sci. 2022; 289: 120242.

[153]

Didamson OC, Chandran R, Abrahamse H. Aluminium phthalocyanine-mediated photodynamic therapy induces ATM-related DNA damage response and apoptosis in human oesophageal cancer cells. Front Oncol. 2024; 14: 1338802.

[154]

Ansari AA, Parchur AK, Li Y, Jia T, Lv R, Wang Y, et al. Cytotoxicity and genotoxicity evaluation of chemically synthesized and functionalized upconversion nanoparticles. Coord Chem Rev. 2024; 504: 215672.

[155]

Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med. 2000; 28: 537-48.

[156]

Shukla RK, Badiye A, Vajpayee K, Kapoor N. Genotoxic Potential of Nanoparticles: Structural and Functional Modifications in DNA. Front Genet. 2021; 12: 728250.

[157]

Swart LE, Fens MHAM, van Oort A, Waranecki P, Mata Casimiro LD, Tuk D, et al. Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles. Pharmaceutics. 2023; 15: 1603.

[158]

Danilatou V, Lydaki E, Dimitriou H, Papazoglou T, Kalmanti M. Bone marrow purging by photodynamic treatment in children with acute leukemia: cytoprotective action of amifostine. Leuk Res. 2000; 24: 427-35.

[159]

Nguyen AK, Patel R, Noble JM, Zheng J, Narayan RJ, Kumar G, et al. Effects of subcytotoxic exposure of silver nanoparticles on osteogenic differentiation of human bone marrow stem cells. Appl Vitr Toxicol. 2019; 5: 123-33.

[160]

Mbeh DA, Akhavan O, Javanbakht T, Mahmoudi M, Yahia L. Cytotoxicity of protein corona-graphene oxide nanoribbons on human epithelial cells. Appl Surf Sci. 2014; 320: 596-601.

[161]

Hashemi E, Akhavan O, Shamsara M, Rahighi R, Esfandiar A, Tayefeh AR. Cyto and genotoxicities of graphene oxide and reduced graphene oxide sheets on spermatozoa. RSC Adv. 2014; 4: 27213-23.

[162]

Coccini T, Pignatti P, Spinillo A, De Simone U. Developmental Neurotoxicity Screening for Nanoparticles Using Neuron-Like Cells of Human Umbilical Cord Mesenchymal Stem Cells: Example with Magnetite Nanoparticles. Nanomaterials (Basel). 2020; 10: 1607.

[163]

Lisek K, Campaner E, Ciani Y, Walerych D, Del Sal G. Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget. 2018; 9: 20508-23.

[164]

Luo S, Lei K, Xiang D, Ye K. NQO1 Is Regulated by PTEN in Glioblastoma, Mediating Cell Proliferation and Oxidative Stress. Oxid Med Cell Longev. 2018; 2018: 9146528.

[165]

Pellosi DS, Paula LB, de Melo MT, Tedesco AC. Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. Mol Pharm. 2019; 16: 1009-24.

[166]

Kang JH, Ko YT. Dual-selective photodynamic therapy with a mitochondria-targeted photosensitizer and fiber optic cannula for malignant brain tumors. Biomater Sci. 2019; 7: 2812-25.

[167]

Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther. 2004; 1: 27-42.

[168]

Mafukidze DM, Sindelo A, Nyokong T. Spectroscopic characterization and photodynamic antimicrobial chemotherapy of phthalocyanine-silver triangular nanoprism conjugates when supported on asymmetric polymer membranes. Spectrochim Acta A Mol Biomol Spectrosc. 2019; 219: 333-45.

[169]

Sekkat N, van den Bergh H, Nyokong T, Lange N. Like a bolt from the blue: phthalocyanines in biomedical optics. Molecules. 2011; 17: 98-144.

[170]

De Paula LB, Primo FL, Pinto MR, Morais PC, Tedesco AC. Evaluation of a chloroaluminium phthalocyanine-loaded magnetic nanoemulsion as a drug delivery device to treat glioblastoma using hyperthermia and photodynamic therapy. RSC Adv. 2017; 7: 9115-22.

[171]

Primo FL, Rodrigues MM, Simioni AR, Lacava ZG, Morais PC, Tedesco AC. Photosensitizer-loaded magnetic nanoemulsion for use in synergic photodynamic and magnetohyperthermia therapies of neoplastic cells. J Nanosci Nanotechnol. 2008; 8: 5873-7.

[172]

Bolfarini GC, Siqueira-Moura MP, Demets GJ, Morais PC, Tedesco AC. In vitro evaluation of combined hyperthermia and photodynamic effects using magnetoliposomes loaded with cucurbituril zinc phthalocyanine complex on melanoma. J Photochem Photobiol B. 2012; 115: 1-4.

[173]

Yi G, Gu B, Chen LK. The safety and efficacy of magnetic nano-iron hyperthermia therapy on rat brain glioma. Tumour Biol. 2014; 35: 2445-9.

[174]

Teng CW, Amirshaghaghi A, Cho SS, Cai SS, De Ravin E, Singh Y, et al. Combined fluorescence-guided surgery and photodynamic therapy for glioblastoma multiforme using cyanine and chlorin nanocluster. J Neurooncol. 2020; 149: 243-52.

[175]

Joniová J, Kazemiraad C, Gerelli E, Wagnières G. Stimulation and homogenization of the protoporphyrin IX endogenous production by photobiomodulation to increase the potency of photodynamic therapy. J Photochem Photobiol B. 2021; 225: 112347.

[176]

Golla C, Bilal M, Dwucet A, Bader N, Anthonymuthu J, Heiland T, et al. Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. Cancers (Basel). 2021;13:4123.

[177]

Ma S, Wang F, Dong J, Wang N, Tao S, Du J, et al. Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy. J Photochem Photobiol B. 2022; 234: 112537.

[178]

Zhang C, Wu J, Liu W, Zheng X, Zhang W, Lee CS, et al. Hypocrellin-Based Multifunctional Phototheranostic Agent for NIR-Triggered Targeted Chemo/Photodynamic/Photothermal Synergistic Therapy against Glioblastoma. ACS Appl Bio Mater. 2020; 3: 3817-26.

[179]

Zhang X, Guo M, Shen L, Hu S. Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. Photodiagnosis Photodyn Ther. 2014; 11: 603-12.

[180]

Shinoda Y, Kujirai K, Aoki K, Morita M, Masuda M, Zhang L, et al. Novel Photosensitizer β-Mannose-Conjugated Chlorin e6 as a Potent Anticancer Agent for Human Glioblastoma U251 Cells. Pharmaceuticals (Basel). 2020; 13: 316.

[181]

Tsai YC, Vijayaraghavan P, Chiang WH, Chen HH, Liu TI, Shen MY, et al. Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal/Photodynamic Therapies of Brain Glioblastoma. Theranostics. 2018; 8: 1435-48.

[182]

Kim HS, Seo M, Park TE, Lee DY. A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy. J Nanobiotechnology. 2022; 20: 14.

[183]

Rodriguez B, Rivera D, Zhang JY, Brown C, Young T, Williams T, et al. Magnetic Hyperthermia Therapy for High-Grade Glioma: A State-of-the-Art Review. Pharmaceuticals (Basel). 2024; 17: 300.

[184]

Skandalakis GP, Rivera DR, Rizea CD, Bouras A, Jesu Raj JG, Bozec D, et al. Hyperthermia treatment advances for brain tumors. Int J Hyperthermia. 2020; 37: 3-19.

[185]

Ibarra LE, Yslas EI, Molina MA, Rivarola CR, Romanini S, Barbero CA, et al. Near-infrared mediated tumor destruction by photothermal effect of PANI-Np in vivo. Laser Phys. 2013; 23: 066004.

[186]

Beola L, Iturrioz-Rodríguez N, Pucci C, Bertorelli R, Ciofani G. Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme. ACS Nano. 2023; 17: 18441-55.

[187]

Shirvalilou S, Khoei S, Esfahani AJ, Kamali M, Shirvaliloo M, Sheervalilou R, et al. Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review. J Neurooncol. 2021; 152: 419-28.

[188]

Lv Z, Cao Y, Xue D, Zhang H, Zhou S, Yin N, et al. A multiphoton transition activated iron based metal organic framework for synergistic therapy of photodynamic therapy/chemodynamic therapy/chemotherapy for orthotopic gliomas. J Mater Chem B. 2023; 11: 1100-7.

[189]

Du L, Wang P, Huang H, Li M, Roy S, Zhang Y, et al. Light-activatable and hyperthermia-sensitive “all-in-one” theranostics: NIR-II fluorescence imaging and chemo-photothermal therapy of subcutaneous glioblastoma by temperature-sensitive liposome-containing AIEgens and paclitaxel. Front Bioeng Biotechnol. 2023; 11: 1343694.

[190]

Huang X, Wu J, He M, Hou X, Wang Y, Cai X, et al. Combined Cancer Chemo-Photodynamic and Photothermal Therapy Based on ICG/PDA/TPZ-Loaded Nanoparticles. Mol Pharm. 2019; 16: 2172-83.

[191]

MMartínez SR, Odella E, Ibarra LE, Sosa Lochedino A, Wendel AB, Durantini AM, et al. Conjugated polymer nanoparticles as sonosensitizers in sono-inactivation of a broad spectrum of pathogens. Ultrasonics. 2024; 137: 107180.

[192]

Huang Y, Ouyang W, Lai Z, Qiu G, Bu Z, Zhu X, et al. Nanotechnology-enabled sonodynamic therapy against malignant tumors. Nanoscale Adv. 2024; 6: 1974-91.

[193]

Shan T, Wang W, Fan M, Bi J, He T, Sun Y, et al. Effective glioblastoma immune sonodynamic treatment mediated by macrophage cell membrane cloaked biomimetic nanomedicines. J Control Release. 2024; 370: 866-78.

[194]

Wu H, Gao X, Luo Y, Yu J, Long G, Jiang Z, et al. Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment. Adv Sci (Weinh). 2022; 9: e2203894.

PDF (9189KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉